Uzbekistan: a faster route in.
One of Central Asia's largest markets, growing fast, with registration review times cut sharply in November 2025.
38.2 million (1 Jan 2026)
about USD 2bn, up 18%
about USD 2bn
60–120 days by category
Growing, and still import-led.
Fast growth
Pharmaceutical turnover reached about USD 2bn in 2025, up 18% on 2024.
Import-led
Medicine imports were about USD 2bn in 2025. The government is pushing local production to reduce them.
Generics favoured
Generics get a shortened registration period under the November 2025 reform.
Review times by safety category.
| Review time | Before Nov 2025 | |
|---|---|---|
| Lowest-risk category | 60 days | 150 days |
| Category 2 | 90 days | — |
| Higher-risk categories | 120 days | — |
| Generics | Shortened registration period | — |
Official review times. Real timelines add questions. Registrations are always held in your name.
Move early, while the clock is short.
Short review times reward manufacturers who are ready now.
The shortened route makes well-priced generics the natural first wave.
Policy favours local manufacturing over time. Enter with that in mind.
Request a market read for Uzbekistan.
Send us your portfolio. We reply within one working day.
- UK · WhatsApp
- +44 7466 253544
- Kazakhstan · WhatsApp
- +7 708 692 2409
- Pakistan
- +92 325 4307967
- [email protected]